Effect of drug sample removal on prescribing in a family practice clinic

Annals of Family Medicine

Volumn 8, Issue 5, 2010, Pages 402-409

  Hartung, Daniel M ^a   Evans, David ^b   Haxby, Dean G ^a   Kraemer, Dale F ^a   Andeen, Gabriel ^c   Fagnan, Lyle J ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b Madras Medical Group   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Health care delivery; Health policy; Health services research

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; CLINICAL PRACTICE; DRUG INDUSTRY; DRUG UTILIZATION; ECONOMICS; GENERAL PRACTICE; HUMAN; MARKETING; METHODOLOGY; PRESCRIPTION; RURAL POPULATION; STATISTICS; UNITED STATES;

DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FAMILY PRACTICE; HUMANS; MARKETING; OREGON; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; RURAL POPULATION;

EID: 77957729105     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1135     Document Type: Article

References (27)

1. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7): 673-681.
2. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5(1):e1.
3. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(1):4-8.
4. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15(7):478-483.
5. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ. 1993;149(10):1401-1407.
6. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990;5(3):240-243.
7. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102(1):270-273.
8. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26(12):1183-1189.
9. Symm B, Averitt M, Forjuoh SN, Preece C. Effects of using free sample medications on the prescribing practices of family physicians. J Am Board Fam Med. 2006;19(5):443-449.
10. Blake RL Jr, Early EK. Patients' attitudes about gifts to physicians from pharmaceutical companies. J Am Board Fam Pract. 1995;8(6):457-464.
11. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351(18):1885-1890.
12. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003;163(18):2213-2218.
13. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287(5):612-617.
14. Eaton L. Readers want transparency in link between doctors and drug firms. BMJ. 2003;326(7403):1352.
15. Scherer FM. The pharmaceutical industry-prices and progress. N Engl J Med. 2004;351(9):927-932.
16. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338(2):101-106.
17. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-selfregulation in the shadow of federal prosecution. N Engl J Med. 2004;351(18):1891-1900.
18. Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach. Acad Med. 2006;81(2):154-160.
19. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
20. Miller DP, Mansfield RJ, Woods JB, Wofford JL, Moran WP. The impact of drug samples on prescribing to the uninsured. South Med J. 2008;101(9):888-893.
21. Brewer D. The effect of drug sampling policies on residents' prescribing. Fam Med. 1998;30(7):482-486.
22. PhRMA. PhRMA Defends Distribution of Pharmaceutical Samples; 2008. http://www.phrma.org/news_room/press_releases/phrma_defends_distribution_of_pharmaceutical_samples.
23. Tjia J, Briesacher BA, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: a national survey. J Gen Intern Med. 2008;23(6):709-714.
24. Cutrona SL, Woolhandler S, Lasser KE, et al. Free drug samples in the United States: characteristics of pediatric recipients and safety concerns. Pediatrics. 2008;122(4):736-742.
25. Cutrona SL, Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98(2):284-289.
26. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46(4):394-402.
27. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295(4):429-433.